ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.
2 other identifiers
interventional
N/A
1 country
8
Brief Summary
The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
8 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 10, 2003
CompletedFirst Posted
Study publicly available on registry
January 14, 2003
CompletedJuly 20, 2006
July 1, 2006
January 10, 2003
July 18, 2006
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.
- Have received no prior chemotherapy for your disease.
- Have at least one measurable lesion.
- have an adequate performance status.
- Sign an informed consent form.
You may not qualify if:
- Have previously received chemotherapy for your lung cancer.
- Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.
- Have received radiation therapy within the last 1-2 weeks.
- Have brain metastasis that is uncontrolled.
- Have active infection or other serious condition.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (8)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Springdale, Arkansas, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Los Angeles, California, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Fort Myers, Florida, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Miami, Florida, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Latham, New York, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Burlington, North Carolina, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Chapel Hill, North Carolina, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Charleston, South Carolina, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
January 10, 2003
First Posted
January 14, 2003
Last Updated
July 20, 2006
Record last verified: 2006-07